Primed for Growth, Inpharmatica Signs Two Pharma Deals, Appoints New CEO | GenomeWeb

Flush with cash from a recent financing round, Inpharmatica is stepping up its growth strategy to address what the company’s newly appointed CEO describes as “a bounty of opportunity” for the London-based firm.

Last week, Inpharmatica announced that it had appointed John Lisle as its new chief executive in a bid to expand its commercial operations. Lisle, whose prior experience includes marketing and business development at AstraZeneca and GlaxoSmithKline, replaces Malcom Weir in the company’s top spot.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.